| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
23 |
/ |
2020 |
|
|
|
| |
Data sporządzenia: |
2020-10-22 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Featuring advantages of the CompuFlo® Epidural System and CathCheck™ in interview
with a key opinion leader
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer",
“Milestone"_ today announced that Milestone Scientific Inc., the licensor of computer-controlled
injection and drug delivery technology and the majority shareholder of Milestone Medical
Inc. has published a video interview with a key opinion leader, Dr. Ayman A. Alian,
MBChB, Associate Professor of Anesthesiology and Division Chief of Obstetric & Gynecological
Anesthesiology at the Yale School of Medicine. The interview, which highlights the
advantages of the CompuFlo® Epidural System and CathCheck™, is available at: https://www.milestonescientific.com/news-media/presentations
Dr. Alian discusses the benefits of the CompuFlo® Epidural System and CathCheck™,
including verification of epidural placement during an epidural procedure and confirmation
of catheter placement. The other advantages of CompuFlo® Epidural System and CathCheck™
include: improving the block, helping the medical practitioner to make a decision,
decreasing complications and the length of stay in the hospital as well as improving
patient satisfaction.
The Board of Directors of the Company is grateful to Dr. Alian for his leadership
in adopting the CompuFlo® Epidural System and CathCheck™ as part of his practice.
The Board of Directors of the Company believes the support from Dr. Alian and other
anesthesiologists is further validation of its technology and advances towards the
goal of CompuFlo® and CathCheck™ becoming the new standard of care.
|
|
|
RB_ASO: Featuring advantages of the CompuFlo® Epidural System and CathCheck™ in interview
with a key opinion leader 
